Skip to main content

Table 2 Clinicopathological characteristics according to HER2 protein expression status

From: Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up

Item

HER2 negative

N = 181

HER2 overexpression

N = 30

P value

Age (year, Mean ± SD)

61.4 ± 9.7

62.3 ± 10.3

0.737

Sex (Male, %)

138 (76.2)

24 (80.0)

0.652

Tumor location (n/%)a

  

0.033

Upper 1/3

49 (27.1)

14 (46.7)

 

Middle 1/3

26 (14.4)

6 (20.0)

 

Lower 1/3

106 (58.6)

10 (33.3)

 

Gross type (n/%)

  

0.183

Elevated

79 (43.6)

14 (46.7)

 

Flat

58 (32.0)

13 (43.3)

 

Depressed

44 (24.3)

3 (6.4)

 

Depth of invasion (n/%) a

  

0.147

Mucous layer

168 (92.8)

25 (83.3)

 

Submucosa

13 (7.2)

5 (16.7)

 

Differentiated types (n/%)a

  

0.371

Differentiated

170 (93.9)

30 (100.0)

 

Undifferentiated

11 (6.1)

0 (0.0)

 

Tumor size (n/%) a

  

0.775

 ≤ 2 cm

155 (85.6)

27 (90.0)

 

 > 2 cm

26 (14.4)

3 (10.0)

 

Lymphovascular infiltration (n/%)a

  

0.461

Present

3 (1.7)

1 (3.3)

 

Absent

178 (98.3)

29 (96.7)

 

Resection margin (n/%)a

  

1.000

Positive

6 (3.3)

1 (3.3)

 

Negative

175 (96.7)

29 (96.7)

 

Current gastric ulcera

26 (14.4)

4 (13.3)

1.000

Current HP infectiona

24 (13.3)

2 (6.7)

0.547

  1. aTested by Fisher exact test